Member Info for Al180

The companies plans are to target about 1% of North American hospitals after FDA approval, this being the top 100 leading academic establishments. This is how MRI was introduced to the market, it's worth noting that back in the day Richard Hullihen set up joint ventures in Japan to manufacture MRI machines and they now have more MRI per population than any other country.
The top 100 hospitals alone would transform the business into a decent company. Listening to some pre FDA approval presentations they were already talking to the reimbursement side of the industry and were confident that the technology made economic scene, this was also on a much quicker timescale than any plans to enter the market in a significant way.

I've had many bad investments on AIM, the common them was an inexperienced BOD who hadn't put much of their own money into buying shares, we have Directors with plenty of skin in the game that are top quality.
Worth reading if you haven't familiarised yourself with all the directors.
hTtps://www.polarean-ir.com/content/investors/board

The BBC in January covered a study into long covid using our technology, this showed lung damage that had not been detected using traditional methods. I remember this on BBC TV world news when I was in Asia at the time, although nobody has heard of Polarean the technology has been highlighted on a global news channel.

This is a comment from the lead researcher..............

"Lead researcher and lung specialist Dr Emily Fraser said it was frustrating having people coming into clinic and not being able to explain to them exactly why it was that they were breathless. Often X-rays and CT scans show no abnormalities." hTtps://www.bbc.co.uk/news/health-60154398

I admit I know little about commercialisation in this industry but if I had a lung problem and was aware of a non radioactive superior technology I would be looking for a hospital that could provide it.

So the top hospitals in north America wont spend a relatively small amount of money on a technology that enhances the existing MRI machines to see things that presently can't be detected?

Polarean have previously stated that they would initially target the top 250 Hospitals in North America, there are 35000 MRI Machines worldwide so a tiny part of the potential market, the sale of 250 units would make them big company alone.

I remember this story being covered on the BBC world news when I was in Thailand and believe it was broadcast in the UK. In a later online podcast with a guy from Amati as a guest, he said Polarean not being mentioned in the article was because they weren't financially involved in the trail.
It seems obvious there is a need for this safer and more efficient way of doing lung scans and with the technology also enhancing the current solution it should make economic sense as well.

At the end of the article in my previous post they talk of the FDA being really interested in the results of these tests due to possible future health warnings for E-cigarettes, it would look a bit odd if the FDA used evidence from tests using Polarean technology and never approved it.

The university of virginia link from February talks about possible risks from vaping that I don't remember being highlighted before

"Potential Significant Health Effects of E-Cig Use
In a recently published pilot study, UVA researchers found that although young vape users have a normal CT lung scan and PFT, the HXeMRI revealed they had decreases in gas uptake by tissue and blood. “In order to compensate for this, they were flowing double the amount of blood to catch oxygen,” notes Shim.

Given vaping’s widespread use and immense popularity among teenagers and young adults, there is major concern over its long-term health impact.

In their pilot study, the UVA researchers write, “We anticipate that HP129Xe MRI can help characterize early-stage pulmonary pathophysiology in three distinctive microcompartments of the e-cigarette users’ lungs: airspaces, alveolar-interstitial tissues, and capillaries. This knowledge can inform us about subclinical but potentially significant health effects related to e-cigarette use.”

Enrolling E-Cig Users in a Pivotal Study
Along with Duke University, UVA Health is actively recruiting 21- to 30-year-old e-cig users for a 2-year study using HXeMRI to look for lung damage from vaping. The Duke and UVA research group has also applied for NIH funding to do a 5-year trial to further assess e-cig’s long-term pulmonary impact.

Shim says, “I think the FDA is really interested in these studies, which are needed before health warnings can be added to e-cigs that are marketed as a ‘safe’ alternative to cigarette smoking. It took 30 years of research before warning labels were put on regular cigarettes. Hopefully, with better diagnostic technology it won’t take that long with e-cigs.”

This chart show historic UK tax revenue from oil and gas, it highlights how much the government could of recovered from tax at reasonable rates if the industry had been supported, not to mention shipping gas from around the world to prop us up.

hTtps://www.reuters.com/graphics/BRITAIN-OIL/TAX/akpezrnzavr/chart.png

Maybe some big fish are waiting for FDA approval before investing, there will probably be buying opportunities at a reasonable price after approval due to profit taking and if you are a fund manager you don't risk looking reckless for investing a company that never gets it product approved.

Hi Marcus, I think you and Charles covered the relevant points well. The quality of the directors, the superiority of the product, the market opportunity, the level of demand and the nice problem they have of getting increased capacity in place.
I think the only other thing I would of mentioned are the barriers to entry for any potential new suppliers.
Regarding future announcements we have been told of a significant contact that should be signed before the end of the year, considering we have had some significant contracts signed already this will hopefully be a talking point
Good luck with the podcasts.

Shell and BP are not even in the top three of north sea gas producers yet the media implies that these are the companies that would be hit with a North sea windfall tax. The tax for north sea companies is now 65% why is this not being mentioned? when I tell people this they are quite shocked.

Current forecasts are hopefully the tip of the iceberg as they don't include the prospective pipeline which is twice the size of contracted orders. listening to recent presentations and Q&A the criteria for the prospective pipeline is quite strict in that it relates to a planned model with a future start date that the OEM and Surface Transforms have done engineering work on.

I took up my subscription shares but didn't apply for more, i'm already breaking my investment rules by holding so many.
Agree DamayHill, In 5 years time we should have 2 factories turning over £150 million and probably more facilities in other locations around the world on current form.

Is it not the case that on approval the polarisers already in place in research hospitals would also be used commercially and start providing further income?

This is from Polareans website under "Ongoing Xenon MRI Research"

"With a visual understanding of lung function, researchers may be able to use Xenon MRI technology to gain new insights into a number of pulmonary diseases and to evaluate new therapeutic agents and procedures"

There was no movement on level 2 data at the reported time of the £506k trade which tells me the this is a buy trade that has been worked through the day, the biggest clue is the share price.

Polarean are in a better position now than when the SP was at all time highs.
The FDA only want clarification on technical issues, we have passed on the safety and effectiveness of our product.
There has been another year to secure potential customers and additional units have been sold to research hospitals which will become commercial on approval.
Reviews from research establishments in the USA and UK have shown this product is needed and enhances the technology currently in place.

Share price is suffering which is understandable as we didn't get approved the first time and the markets are in fear mode but the current market cap is £90 million for a company that will revolutionise MRI scans worldwide and provide every dose of gas on top of machine sales.

Hopefully there will be plenty of news flow following approval as Polarean have had extra time to talk to potential customers and refine commercial launch during the period of delay.
I can't see myself selling any shares immediately before or after approval especially with short term traders probably suppressing the SP around this time.

Just added a few at 54.4p showing as a sell.